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Expression of HER-2/neu in Oral Squamous Cell Carcinoma
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Abstract
Background: HER-2/neu is a member of the human epidermal growth factor (HER) family of transmembrane
tyrosine kinases, which is significantly associated with the pathogenesis of various cancer types. The aim was to
evaluate the expression of HER-2/neu in oral squamous cell carcinoma (OSCC) as a potential biomarker to target
antigens for specific immunotherapy in OSCC. Methods: One hundred and forty histologically diagnosed OSCC cases
were identified. Four to five-micrometer thick formalin-fixed, paraffin-embedded tumor sections were stained with
Haematoxylin and Eosin (H and E). Histological grade was assessed according to WHO/Broders classification, while
tumors were staged according to the American Joint Committee on Cancer (AJCC) TNM classification from stage I
to IV. Immunohistochemistry was performed by using Rabbit monoclonal antibody against HER-2/neu (EP700Y, cell
marquee and diluted 1:50). FISH was performed on positive cases using Vysis PathVysion HER-2 DNA probe (Abbott
USA). Probes consist of LSI HER gene spectrum orange and control probe CEP 17 spectrum green. Results: In this
study, males were mostly effected (64.3%) with buccal mucosa (49%) to be the commonly involved site for OSCC.
Majority of cases were moderately differentiated (62.1%) and 50.7% tumors were Stage IV. HER-2/neu was found to
be positive (2+) in one case of OSCC, however weak to moderate complete membrane staining was observed in >10%
of the tumor cells. One hundred and thirty nine cases were HER-2/neu negative. FISH analysis of HER-2/neu positive
cases also showed gene amplification (Her2-neu/ CEp 17 = 225/33 = 7.2). Conclusions: The study showed disparity
in the expression of HER-2/neu in OSCC, which is due to multiple reasons. Therefore therapy against HER-2/neu in
OSCC is debatable.
Keywords: Oral squamous cell carcinoma- human epidermal growth factor receptor-2- erbB2- immunohistochemistry
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Introduction
The terminology oral cancer is interchangeable with
oral squamous cell carcinoma (OSCC) which is estimated
to be 90% of all oral neoplasms (Choi and Myers, 2008).
Oral cancer is considered as one of the chief public health
issue worldwide, accounting for 2-4% of all cancer cases.
Despite significant improvements achieved during the
last decades in its detection, prevention, and treatment;
outcome and prognosis related to OSCC cure and survival
is poor due to treatment resistance and tumor recurrence.
For most countries, age-adjusted death rates have been
estimated to be 3–4 per 100,000 in men and 1.5–2.0 per
100,000 for women (Bray et al., 2018). The mortality rate
is steadily even in the younger generation. The removal
of two main risk factors: cigarette smoking and alcohol
consumption can potentially reduce the incidence of

oral cancer up to three-quarters (Beynon et al., 2018).
Regardless of the accessibility of oral cavity for clinical
examination and advance research into pathogenesis and
management, the 5-year survival rate for OSCC has not
improved (Mirza et al., 2016). Many molecular markers
have been identified reflecting the aggressive behavior
of OSCC, however none of these markers have shown
unequivocal prognostic or predictive significance (Sharma
et al., 2013; Gupta et al., 2016).
The HER-2/neu (ErbB) protein is a tyrosine kinase
receptor belonging to tyrosine kinase family comprising
of; erbB1, erbB2, erbB3, and erbB4. These proteins play an
essential part in cellular growth and differentiation (Mirza
et al., 2016; Seifi et al., 2009). The dysregulation of these
receptors, lead to an uncontrolled cell cycle, resistance
to apoptotic stimuli, invasiveness, chemo-resistance, and
angiogenesis (Pardis et al., 2012; Salem et al., 2006).
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Evidence suggests overexpression of HER-2/neu in
advanced diseases, metastasis-associated with poor clinical
outcomes in breast and ovarian carcinoma, osteosarcoma;
endometrial, salivary, and gastric carcinomas (Bonelloet
al., 2018; Khan et al., 2002; Omar et al., 2015). Research
studies have correlated the immunohistochemical
expression of Her-2/neu with a more aggressive behavior
in breast cancer leading to shorter overall survival. Ramic
et al., (2013) stated that HER-2/neu is overexpressed in
approximately 20-25% of cases of invasive breast cancer
(BC), resulting in tumors with more aggressive biological
behavior leading to poor prognosis, shorter survival and
increased risk of death.
In a study by Ahmed Al Aziz et al., (2017) it was
concluded that Her2/neu can be used as an independent
prognostic marker for tumor recurrence after complete
resection of gastrointestinal stromal tumors. Concerning
oral squamous cell carcinoma, the biological behavior
of tumor is highly variable and studies on HER-2/neu
are discordant and insufficient (Dragomir et al., 2012;
Kouhsoltani et al., 2015; Schartinger et al., 2009). The
incidence of Her2/ neu overexpression has ranged from
0 to 40% (Angiero et al., 2008; Cavalot et al., 2007;
Sardari et al., 2012). By contrast, Singla et al., (2018)
reported Her-2/neu expression to be negative, though
cytoplasmic positivity was observed in a few cases.
Continued therapeutic developments have resulted in
targeted therapies against HER-2/neu in the breast,
gastric and lung carcinomas (Liu et al., 2010; Moelanset
al., 2011). Bang et al conducted a phase 3, randomized
controlled trial and concluded that trastuzumab in
combination with chemotherapy exhibits both efficacy
and safety for the first-line treatment of advanced gastric
cancer with expression of HER-2 (Bang et al., 2010).
In a similar report, Ohashi et al., (2017) reported that
approximately 5% of NSCLC tumors possess HER2
alterations, and Trastuzumab emtansine (an anti-HER2
antibody conjugated with a vinca alkaloid) has shown
excellent antitumor effects against HER2/neu. The therapy
targeting this pathway in OSCC could uncover valuable
evidence, and a clinical trial about this signal would be
worthy. Therefore, the present study aimed to evaluate the
expression of HER-2/neu in OSCC to identify a potential
biomarker, potentially used as a target antigen for specific
immunotherapy against OSCC.

Materials and Methods
This study included 140 cases of Oral Squamous
Cell Carcinoma (OSCC) presenting to the maxillofacial
department of Ziauddin college of Dentistry. The processing
was performed at Histopathology Laboratory of Ziauddin
Hospital, Karachi, Pakistan. The clinic-pathologic data
of each case was collected using a questionnaire. Cases
without complete clinicopathologic data, inadequate
paraffin-embedded material, incisional biopsies, and
recurrent OSCC were excluded. Specimens were routinely
processed, fixed overnight in 10% buffered formalin
and were examined grossly according to the standard
guidelines. Four to five-micrometer thick formalin-fixed,
paraffin-embedded tumor sections were stained with
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H and E. Histological grade was assessed according to
WHO/Broders classification (El-Mofty, 2007; Schwab,
2011). Tumors were staged according to the American
Joint Committee on Cancer (AJCC) TNM classification
seventh edition from stage I–IV. The ethics committee
of Ziauddin University, College of Dentistry, provided
ethical approval.
Immunohistochemistry evaluation
Immunohistochemistry was performed by using Rabbit
monoclonal antibody against HER-2/Neu (EP700Y, cell
marquee and diluted 1:50). The HER-2 protein immuneexpression was analyzed using the American Society of
Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines for Her-2 testing in Breast
Cancer, as shown below (Bernardes et al., 2011).
‘0’- no staining or membrane staining is observed in
< 10% of the tumor cells;
‘1+’- faint/barely perceivable membrane staining is
detected in > 10% of the tumor cells, and only part of the
membrane is stained;
‘2+’-weak to moderate complete membrane staining
is observed in >10% of the tumor cells;
‘3+’-strong complete membrane staining is observed
in > 30% of the tumor cells.
Fluorescence in situ hybridization
A 4-5-micron paraffin-embedded tissue section was
taken on a positively charged slide, the sample was
pretreated with xylene to remove paraffin and ethanol
then subjected to proteinase treatment (pepsin) before
proceeding to apply FISH probe. Vysis PathVysion
HER-2 DNA probe (Abbott USA) was used. Probes
consisted of LSI HER gene spectrum orange and control
probe CEP 17 spectrum green. The probe is applied to the
slide and placed in thermobrite for denaturation at 73°C
for 7 minutes and hybridization for 24hrs. Post washing
was performed after 24hrs with a reagent NP-40 to remove
the unattached probe and apply Dapi (counterstain). On
fluorescent microscopy, approximately 20 nuclei were
counted with a red signal representing the HER-2 gene
and green signal CEP 17.
Interpretation of FISH
FISH was analyzed using the American Society of
Clinical Oncology/College of American Pathologists
(ASCO/CAP) guidelines for Her-2 testing in breast
cancer as shown below (Richardson et al., 2012; Wolff
et al., 2007).
Negative (not amplified) - Average Her2 copy number
< 4.0 signals/ cell.
Equivocal – Average Her2 copy number ≥ 4.0 and <
6.0 signals/ cell.
Positive (amplified) – Average Her2 copy number ≥
6.0 signals/cell.
Statistical analysis
Statistical analysis was performed using the SPSS
software program (v.21.0 for Windows, IBM, Chicago,
IL). Data for categorical variables such as age, gender,
lymph node involvement, site of the primary lesion,
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perineural invasion (PNI), lymphovascular invasion
(LVI), distant metastasis (DM), and stage of the tumor
were expressed in frequencies and percentages. A chisquare test was used among different groups to construct
association. Since tumor size and tumor thickness were
continuous variables so, Kruskal-Willis and MannWhitney test were used to find the difference in the mean
ranks of tumor size and thickness. A p-value of less than
0.05 was regarded as statistically significant.

Results
This cross-sectional study was carried out on 140
OSCC patients, with 90 (64.3%) males and 50 (35.7%)
females. Most of the patients (41; 29.3 %) age ranged
between 49 to 58 years. Buccal mucosa was found to
be the most common site (69; 49.3%), followed by
mandible and tongue (24; 17.1%). Most of the tumors
were moderately differentiated (87; 62.1%) followed
by poorly differentiated (30; 21.3%) and (23; 17.1%)
well-differentiated OSCC. Maximum number of patients
had stage IV tumors (71; 50.7%), followed by stage II (35;
25.0), stage III (24; 17.1%) and stage I (10; 7.1%) tumors.
Lymph node metastasis was present in 51.4% (n = 72)
and absent in 48.5% (n=68) of OSCC patients. The mean
tumor size was 3.4 ± 1.9 (range 0.5-11cm) with the mean
tumor thickness of 1.8 mm (range 0.2-11mm). Perineural
invasion was present in 22.9% and absent in 77.1% of
OSCC patients. While the lymphovascular invasion was
present in 8.6% and absent in 91.4% of OSCC patients.
Distant metastases (Stage IVC) was found in only 8
(5.7%) OSCC patients.
HER-2/neu was found to be positive (2+) in one case
of OSCC, with weak to moderate complete membrane
staining observed in >10% of the tumor cells (Figure
1). The remaining 139 cases were HER-2/neu negative
(Figure 2). FISH analysis of Her2/neu positive case also
showed gene amplification (HER2-neu/ CEp 17 = 225/33
= 7.2) (Figure 3).

Discussion
The immunohistochemical expression of

Figure 1. Immunohistochemical Staining for OSCCShowing Weak to Moderate Dark Brown Membranous
Staining (arrow) of HER-2/neu (2+) 200X. Inset in shows
positive control for Her2/neu expression (invasive ductal
carcinoma of breast, 400X). (Case. No. 90)

Figure 2. Immunohistochemical Expression of HER2/neu in OSCC Showing Negative Expression (200X)
(arrows) (Case. No.68).

Figure 3. Representative FISH Image of OSCC Showing
Interphase Index Using HER-2/CEP 17 Dual-Color
Probe. Her2 gene amplification is seen. Gene signals are
red- labeled, CEP 17 signals are green-labeled (arrow)
(Case. No.90).
Her2/neu in oral cancer has shown wide variation (334%) (Bei et al., 2004; Roberto Bei et al., 2001; Chen et
al., 2003). This disparity in results regarding the HER-2/
neu overexpression is related to clinicopathological
parameters of OSCC (Craven et al., 1992; Field et al.,
1992; Pardis et al., 2012; Rivière, Becker, and Löning,
1991). Hence the role of HER-2/neu in carcinogenesis
of oral squamous cell carcinoma remains controversial.
The present study aimed to evaluate the expression of
HER-2/neu in a subset of South-East Asian population
as data is scarce in such OSCC patients. In the present
study, only one case (0.72%) showed overexpression
(2+) with 139 (99.28%) cases showing no significant
staining of cancer tissue. This is similar to the findings
of previous studies in discrete populations reporting no
overexpression of HER-2/neu in OSCC (Angiero et al.,
2008; Ekberg et al., 2005; Pardis et al., 2012; Sardari et
al., 2012; Shintani et al., 2004). On the other hand, some
studies have reported the overexpression of HER-2/neu
suggesting its use as a marker to differentiate healthy
from cancer tissues (Cavalot et al., 2007; Fonget al., 2008;
Lebeau et al., 2001). On reviewing the current evidence, it
is hypothesized that overexpression of HER-2/neu occurs
only in a small number of OSCC cases. To support our
conclusion, we carried out an in-depth analysis of different
Asian Pacific Journal of Cancer Prevention, Vol 21
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studies by recording the total number of cases studied, the
number of cases showing positive outcomes and intensity
of positive expression (1+, 2+, 3+ and 4+). According
to CAP guidelines for HER-2/neu immunostaining, an
outcome of 3+ is regarded as overexpression of protein
(Richardson et al., 2012; Wolff et al., 2007). Many
of the authors including Chen et al., (2003) reported
overexpression of HER-2/neu in 41% (n=59) cases,
however failed to mention the scores. Similarly, Azemar
et al., (2000) reported the overexpression of HER-2/neu
in 58% of cases (n=45) but did not report the scores.
On the other hand, Fong et al (33) reported HER-2/
neu overexpression in 50% of his cases (12 cases 1+,
and 3 cases 2+), while Seifi et al., (2009) reported
overexpression of HER-2/neu in 72% of OSCC cases (5
cases 1+, 8 cases 2+). However, in both these studies, none
of the cases were 3+ which is regarded as overexpression.
Dragomi et al., (2012) reported five cases as 3+ (n= 44)
while Schartinger et al., (2009) (n=116), (Bernardes, et
al., 2010) (n=46) and Khan et al., (2002) (n=26) reported
only one case with 3+ overexpression.
In a study by Wilkman et al., (1998) only 11 cases
of squamous cell carcinoma reported intense staining of
her2/neu in the poorly differentiated epithelium. While
in the present study, no difference in expression of
HER-2/neu was seen among different histological grades
of OSCC (p=0.23). Beckhardt et al., (1995) revealed
only 6 of 38 (16%) OSCC tissue sections with HER-2
oncoprotein overexpression. While (Stoicanescu et al.,
2013) reported overexpression of HER-2/neu in only 25%
of cases among which, 5.2% were 1+, 14.7% were 2+ and
only four cases had 3+ expression. Hanken et al., (2014)
reported overexpression of HER-2/neu in only 4 cases out
of 196 (1 case 1+, 2 cases 2+ and 1 case 3+) . They also
carried our FISH analysis reporting gene amplification in
6 out of 207 cases, suggesting that these cases can benefit
from antiHER-2 therapy. Birkeland et al., (2016) reported
overexpression in only 2 out of 92 cases of OSCC. Both
the authors concluded that despite this low Her2/neu
overexpression of only 1 – 2%, those few patients could
benefit from anti HER-2 therapy, thus highlighting the
role of this receptor in personalized medicine.
In multiple studies conducted to study HER-2/
neu expression in OSCC, purely membranous staining
(Craven et al., 1992; Hoffmann et al., 2001; Khademi et
al., 2002) or cytoplasmic staining (Angiero et al., 2008;
Craven et al., 1992; Field et al., 1992; Khademi et al.,
2002), and mixed membranous-cytoplasmic staining
(Bei et al., 2004; Craven et al., 1992; Ibrahimet al., 1997;
Rautava et al., 2008; Xia et al., 1997; Xia et al., 1999) have
been reported. In squamous cell carcinoma, cytoplasmic
staining is commonly reported but according to Cavalot et
al., (2007) it is said to be a technical artifact due to crossreactive antibodies possibly with keratin or during antigen
retrieval process. For better, authentic and more reliable
results we considered purely membranous staining as
positive for the cases in the present study.
Literature has shown inconsistency among correlation
of HER-2/neu with clinicopathological parameters of oral
squamous cell carcinoma irrespective of overexpression
of HER-2/neu. In the present study, there was no
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association of HER-2/neu expression with any of the
clinicopathological parameters. This is similar to other
studies (Cavalot et al., 2007; Khan et al., 2002) with no
significant association between HER-2/neu positivity
with age, sex, race, tumor site, tumor stage, grade, and
recurrence. A study by Fong et al., (2008) reported
overexpression of HER-2/neu in stage IV OSCC as
compared to stage I-III OSCC cases. This is in contrasts
with the present study showing no significant association
with tumor stage (p=0.388). Therefore, researchers like
Riviere et al., (1991), Field et al., (1992), Khan et al.,
(2002), Ekberg et al., (2005) and Angiero et al., (2008) did
not suggest HER-2/neu as a prognostic factor or treatment
indicator in OSCC patients. A possible explanation
for disparity among study outcomes is a lack of
standardization of the assay methods (the direct, indirect
technique of immunohistochemistry) and use of different
techniques (immunosorbent assay, radioimmunoassay,
IHC). A careful review of studies showed a variation
in the type of antibody used that recognize different
epitopes of protein (Clone CerbB2, CB11, ICR1b,
polyclonal DAKO, monoclonal enzyme), in addition to
lack of specific criteria for positive staining of HER2/neu
protein (membrane and/ or cytoplasmic). In particular, the
significance of cytoplasmic staining is the most widely
debated question. Gender variation and differences in the
site of primary tumors are also considered to contribute to
this disparity in results (Cavalot et al., 2007).
The present study supports the idea that, despite
low Her2/neu overexpression (1-2 %), patients with
positive results could benefit from anti-cancer/anti-Her2
therapy. As oral cavity is part of gastrointestinal
tract, Her2 testing on gastric biopsies should be
investigated and optimized for immunohistochemical
scoring in OSCC tissues employing future studies.
Further studies are recommended to establish standard
immunohistochemistry staining protocols to aid uniform
reporting of protooncogene in OSCC.
In conclusion, the study showed disparity in the
expression of HER-2/neu in OSCC which is due to
multiple reasons. Therefore therapy against HER-2/neu
in OSCC is debatable.
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